Invivyd Advances COVID-19 Program and Launches Measles Antibody

Invivyd ( (IVVD) ) has provided an update.

On April 9, 2026, Invivyd reported progress in its REVOLUTION program, highlighting that pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION trial of VYD2311 have already accumulated enough to support statistical power for the high end of expected efficacy. The company triggered a pre-specified sample size re-estimation after 1,500 of 1,818 patients reached Day 45, upsizing the study by about 500 subjects, which is expected to shift top-line results from mid-2026 to the third quarter of 2026 while increasing confidence in the robustness of the dataset.

Invivyd also said it has aligned with the U.S. Food and Drug Administration on an initial Pediatric Study Plan for the DRUMMER immunobridging and safety trial, which would support a potential biologics license application for VYD2311 in children aged 0–11 if DECLARATION is successful. Executives framed these developments as strengthening the company’s bid to reposition repeat mRNA COVID-19 boosters as a second-line option and to establish a rapid, regulator-aligned path into pediatric markets, reinforcing Invivyd’s ambition to become a multi-virus infectious disease platform player.

In parallel, Invivyd unveiled VMS063, a novel, half-life-extended monoclonal antibody candidate targeting the measles fusion protein for both treatment and prevention of measles. VMS063 has shown highly potent in vitro neutralization across circulating measles lineages, targets a conserved epitope, and exhibits favorable developability characteristics, and the company has begun IND-enabling activities and regulatory outreach to support rapid clinical development.

The measles program rollout comes amid a sharp resurgence of measles in the U.S. in 2025–2026, with outbreaks across more than 30 states, the first domestic measles deaths in a decade, and an estimated immunity gap involving millions of unprotected children and immunocompromised adults. By advancing what could be a first precision therapy and passive prophylaxis option for measles in high-risk groups such as infants, pregnant women, and immunocompromised patients, Invivyd is seeking to expand its platform beyond COVID-19 and address a growing public health crisis where no approved treatments currently exist.

The most recent analyst rating on (IVVD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Spark’s Take on IVVD Stock

According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.

The score is held back primarily by ongoing losses and sizable cash burn despite improving results, alongside weak technical momentum with the stock trading below key moving averages. Offsetting these are a strong balance sheet with low leverage and encouraging earnings-call execution (Phase 3 enrollment milestone, favorable safety review, and continued PEMGARDA revenue growth).

To see Spark’s full report on IVVD stock, click here.

More about Invivyd

Invivyd, Inc. is a clinical-stage biotech company focused on developing monoclonal antibody therapies for infectious diseases, with lead programs targeting COVID-19 and emerging candidates for measles and RSV. Using proprietary discovery technology, the company aims to build a multi-virus platform that delivers high-value preventive and therapeutic antibodies, particularly for vulnerable populations at elevated risk from respiratory and viral infections.

The company is positioning itself to challenge existing vaccine-centric prevention models in COVID-19 and to establish first- or best-in-class antibody options in areas like measles where no approved treatments currently exist. Its pipeline strategy emphasizes long-acting, high-resistance-barrier antibodies that can support both prophylaxis and treatment, potentially reshaping standards of care and expanding its addressable market across pediatric and adult segments.

Average Trading Volume: 2,839,508

Technical Sentiment Signal: Sell

Current Market Cap: $381.5M

For detailed information about IVVD stock, go to TipRanks’ Stock Analysis page.